Sharpen your approach to high-risk renal cell carcinoma (RCC). In this episode of BackTable Urology, guest Dr. Sumanta (Monty) Pal from City of Hope joins host Dr. Aditya Bagrodia to discuss contemporary kidney cancer treatment and the complexities of perioperative therapy.

---

This podcast is supported by:

Photocure

https://www.photocure.com/

---

SYNPOSIS

The conversation covers the challenging side effects of perioperative treatments, the evolution of therapies from tyrosine kinase inhibitors to modern checkpoint inhibitors, and the introduction of adjuvant therapies. Dr. Pal and Dr. Bagrodia explore the impact of these treatments on patient outcomes, the challenges with current biomarkers, and the potential of emerging trials. The doctors also highlight the importance of personalized RCC management strategies, particularly for high-risk patients and non-clear cell histologies. They also emphasize the need for appropriate patient counseling in this emerging field.

---

TIMESTAMPS

00:00 - Introduction

01:53 - Evolution of Kidney Cancer Treatments

03:30 - Tyrosine Kinase Inhibitors in the 2010s

10:42 - Checkpoint Inhibitor Trials

23:09 - Discussing Adjuvant Therapy with Patients

26:56 - Restaging and Biomarkers

31:58 - Challenges in Adjuvant Immunotherapy

39:57 - Non-Clear Cell RCC

41:42 - Future Directions

---

RESOURCES

Photocure:

https://www.photocure.com/